AI Summary
✦ ClarthaDivi’s Laboratories is a pharmaceutical manufacturer producing generic APIs, intermediates, nutraceuticals, and custom-synthesis products. APIs and intermediates anchor revenue, while contract manufacturing and carotenoids serve pharmaceutical, nutrition, food, beverage, pet-food, and feed customers. Q1FY27 profit surged 65% on strong revenue growth, indicating operating leverage despite stable reported margins. The company is net-cash, with debt/equity of 0.04; ROE is unavailable, limiting returns analysis. Revenue grew 12.3%, while profit increased 17.2%, implying favorable earnings conversion without reported margin expansion. At 85.5x earnings, Divi’s trades at a substantial premium to its growth rate and sector-style manufacturing multiples. The valuation is rich, leaving execution on custom synthesis, API demand, and carotenoid growth as key open questions.
Price Forecast
Probabilistic Range
Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
From 29 analysts
Fundamentals
Fundamentals institutional score is 96 using growth durability 96.4.
Valuation
Valuation institutional score is 17 using relative multiple z-scores where peer dispersion is available.
Analyst Consensus
Analyst View institutional score is 26 using mean target upside -0.0%; dispersion penalty 27.5; recommendation breadth from available consensus.
Technical Structure
Technicals institutional score is 36 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.
Market Sentiment
Recent news flow is balanced or not decisive enough to tilt the tape. Based on 2 recent ticker-linked news items.
Signal Summary
Market intelligence remains Mixed. fundamentals and market sentiment provide support, while valuation and analyst consensus remain considerations.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Trading 42.3% above historical median. Valuation is rising — currently in the strongly overvalued zone (z-score: +2.35). Confidence: 77%.
Live forward EPS implies next-12-month EPS of ₹150.33. Applying the stock's normalized valuation corridor produces a fair range of ₹6,124.44 to ₹9,848.12, with base value near ₹9,022.81 (+8.8% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹150.33
Forward P/E
55.2x
Base Fair Value
₹9,022.81
Fair Range
₹6,124.44 - ₹9,848.12
Upside To Base
+8.8%
Estimate Source
Live forward EPS
Growth Estimate
+65.7%
5Y Average
49.60
Current
85.39
Overvalued
65.51
Undervalued
40.74
5Y Average
31.80
Current
54.75
Overvalued
39.86
Undervalued
23.40
5Y Average
11.39
Current
19.60
Overvalued
14.27
Undervalued
8.38
Peers & Comparison
Sector: Health Care · Theme: Labs & Life Sciences Services
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
APOLLO HOSPITALS ENTER. L APOLLOHOSPHospitals & Diagnostic Centres | +18.1% | 7.7% | 66.0x Premium | +79% vs avg | +23.2% |
HINDALCO INDUSTRIES LTD HINDALCOMetals - Aluminium | +32.1% | 5.5% | 14.4x Undervalued | -61% vs avg | +58.0% |
DR. REDDY S LABORATORIES DRREDDYPharmaceuticals | -5.6% | 10.0% | 29.2x Undervalued | -21% vs avg | -3.9% |
GRASIM INDUSTRIES LTD GRASIMCement | +10.5% | 2.8% | 45.5x Premium | +24% vs avg | +23.4% |
EICHER MOTORS LTD EICHERMOTTrucks & Buses | +31.5% | 23.2% | 38.0x Fair | +3% vs avg | +41.4% |
BSE LIMITED BSEStock Exchanges & Ratings | +64.0% | 48.9% | 52.3x Premium | +42% vs avg | +44.3% |
HCL TECHNOLOGIES LTD HCLTECHIT Services & Consulting | +3.0% | 13.0% | 21.1x Undervalued | -43% vs avg | -8.8% |
BAJAJ AUTO LIMITED BAJAJ-AUTOTwo Wheelers | +64.0% | 16.3% | 27.7x Undervalued | -25% vs avg | +40.9% |
DIVI S LABORATORIES LTD trades at a premium (85.7x vs peer avg 36.8x), implying higher growth or quality expectations from the Labs & Life Sciences Services cohort. Peers include APOLLO HOSPITALS ENTER. L, HINDALCO INDUSTRIES LTD, DR. REDDY S LABORATORIES — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹2.97K CrJun 2026Latest net profit
₹891 CrJun 2026Latest EPS
₹33.56Jun 2026Net margin
42.0%Jun 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Jun 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 1,730 | 1,868 | 1,808 | 2,259 | 2,063 | 2,302 | 2,297 | 2,536 | 2,357 | 2,660 | 2,578 | 2,793 | 2,974 |
| Expenses + | 1,239 | 1,394 | 1,317 | 1,542 | 1,442 | 1,573 | 1,550 | 1,655 | 1,614 | 1,765 | 1,671 | 1,850 | 1,734 |
| Operating Profit | 491 | 474 | 491 | 717 | 621 | 729 | 747 | 881 | 743 | 895 | 907 | 943 | 1,240 |
| OPM % | 28% | 25% | 27% | 32% | 30% | 32% | 33% | 35% | 32% | 34% | 35% | 34% | 42% |
| Other Income + | 80 | 85 | 94 | 79 | 79 | 105 | 82 | 87 | 119 | 146 | 13 | 154 | 63 |
| Interest | 0 | 1 | 0 | 2 | 0 | 1 | 0 | 0 | 3 | 8 | 6 | 6 | 6 |
| Depreciation | 93 | 94 | 95 | 94 | 97 | 98 | 99 | 107 | 112 | 113 | 116 | 120 | 132 |
| Profit before tax | 478 | 464 | 490 | 700 | 603 | 735 | 730 | 861 | 747 | 920 | 798 | 971 | 1,165 |
| Tax % | 28% | 26% | 27% | 24% | 29% | 30% | 19% | 23% | 25% | 24% | 25% | 22% | 24% |
| Net Profit + | 345 | 342 | 358 | 531 | 430 | 518 | 594 | 667 | 557 | 696 | 598 | 756 | 891 |
| EPS in Rs | 13.00 | 12.88 | 13.49 | 20.00 | 16.20 | 19.51 | 22.38 | 25.13 | 20.98 | 26.22 | 22.53 | 28.48 | 33.56 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome